ArticleBMC research notes2025
Microbial diversity in cutaneous leishmaniasis lesions and potential implications for disease progression and treatment outcomes.
Article in BMC research notes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Role of Microbiome and Bacterial Biofilms in the Pathogenesis of Cutaneous Leishmaniasis.Acta parasitologica · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveBeyond the parasitic infection in Cutaneous leishmaniasis (CL), secondary bacterial colonization can influence disease chronicity, delay healing, and reduce treatment efficacy. This study investigated the bacterial diversity in CL lesions, its association with lesion duration, and its potential impact on treatment outcomes among Sri Lankan patients.
resultsFifteen bacterial species were identified, including both Gram-positive and Gram-negative organisms. Staphylococcus aureus was associated with the longest lesion duration (up to 12 months) and extended treatment (15 cycles of intralesional sodium stibogluconate and cryotherapy). In contrast, species such as Kocuria palustris and Acinetobacter baylyi were linked to shorter treatment durations. Multivariate analysis revealed that lesion type significantly influenced treatment duration (P < 0.05), while larger lesion size and diabetes showed marginal associations with prolonged therapy. The presence of opportunistic and antibiotic-resistant species, particularly S. aureus, suggests a potential contributory role of bacterial co-infections in CL progression and highlights the need to consider their presence in treatment planning. Integrating microbial profiling into clinical protocols may enhance treatment efficacy and inform personalized care strategies. However, the limited sample size and convenience-based recruitment may affect the generalizability of these findings, and the potential influence of bacterial colonization on treatment response warrants further investigation in larger cohorts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.